Our breast cancer patient sample size that was used for hormone receptor status (N = 48 breast cancer tissue with known hormone receptor status of breast cancer of 68 total patients) is comparable to other breast cancer studies from Kenya, Uganda, and Tanzania: (N = 34 with hormone receptor status of 129 total patients; [19]); (N = 54 with hormone receptor status of 219 total patients; [28]); (N = 158; [27]); (N = 35 patients with hormone receptor status of 45 total patients enrolled in study; [26]); (N = 65; [25]); and (N = 57 with hormone receptor status of 488 total patients; [29]). The gene discussed is NR4A1; the disease is breast carcinoma.